This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

IgA Nephropathy Market

Market Insights on IgA Nephropathy covering sales outlook, demand forecast & up-to-date key trends

IgA Nephropathy Market by Diagnosis, Diseases Type, Systems, Population Type, Route of Administration, Treatment, End Users & Region – Forecast 2023–2033

IgA Nephropathy Market Snapshot

The global IgA nephropathy market is expected to garner a market value of US$ 41.24 Billion in 2023 and is expected to accumulate a market value of US$ 85 Billion by registering a CAGR of 7.5% in the forecast period 2023-2033. Growth of the IgA nephropathy market can be attributed to growing prevalence of kidney diseases amongst different age groups. The market for IgA nephropathy registered a CAGR of 4.8% in the historical period 2017-2022

IgAN is an autoimmune disease that attacks the kidneys. It affects blood filtration in the small blood vessels of the kidneys. It occurs when an abnormal protein damages the filtering unit (glomerulus) inside the kidneys. This, in turn, causes pain leading to patients undertaking different forms of treatments.

Report Attribute

Details

Expected Market Value (2023)

US$ 41.24 Billion

Anticipated Forecast Value (2033)

US$ 85 Billion

Projected Growth Rate (2023-2033)

7.5% CAGR

Customize this Report

Let us know your requirement to get
100% FREE customization

2017-2022 IgA Nephropathy Market Demand Analysis vs. Forecast 2023-2033

According to market research and competitive intelligence provider Future Market Insights- the market for IgA nephropathy reflected a value of 4.8% during the historical period, 2017- 2022.

The increasing cases of COVID-19 have a direct correlation with the growth of kidney-related diseases. For instance, as per a report published in 2021, titled, "Acute Kidney Injury in COVID-19: 90 Days of the Pandemic in a Brazilian Public Hospital," 4–37% of COVID-19 cases involve the kidneys, and acute kidney diseases have an incidence of 50% among hospitalized COVID-19 patients. Thus, it has been found that the COVID-19 virus is having an impact on the kidney of patients, which in turn, is expected to increase the burden of kidney disorders in the near future and fuel the market growth.

The major factors for the growth of the IgA nephropathy market include the increasing incidence of chronic kidney diseases, technological advancements in diagnostic tests for kidney diseases, and the increasing need for early detection. Thus, the market for IgA nephropathy is expected to register a CAGR of 7.5% in the forecast period 2023-2033.

Which are Some Prominent Drivers of IgA Nephropathy Market?

Conventional treatments and approval of medication favouring growth of market

Conventional major treatments to manage IgAN include ACE inhibitors (angiotensin-converting enzyme inhibitors) and ARBs (angiotensin II receptor blockers), to manage symptoms like high blood pressure, etc. Other treatments include corticosteroids, to slow the progression of the disease, and other immunosuppressants like MMF, cyclophosphamide, etc.

TARPEYO (budesonide) delayed release capsules, is the first and only FDA approved drug for the treatment of IgAN. It is indicated for IgAN patients, who at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥ 1.5 g/g. It was approved by the US FDA in December 2021, under accelerated approval pathway, recognizing the urgent need for safe and efficacious therapies.

Availability of therapeutic treatments creating lucrative opportunities for IgA nephropathy market

Tarpeyo: Calliditas Therapeutics AB

Tarpeyo (developed under the project name Nefecon) is a patented oral formulation of a potent and well-known active substance- budesonide for targeted release. The formulation is designed to deliver the drug to the Peyer’s patch region of the lower small intestine, where the disease originates, as per the predominant pathogenesis models. Tarpeyo is derived from the TARGIT technology, which allows the substance to pass through the stomach and intestine without being absorbed and released in a pulse-like fashion only when it reaches the lower small intestine.

In addition to its potent local effect, another advantage of using this active substance is its very low bioavailability, i.e., around 90% of it is inactivated in the liver before it reaches the systemic circulation. This means that a high concentration can be applied locally where needed but with only very limited systemic exposure and side effects.

Sparsentan: Travere Therapeutics, Inc

Sparsentan is a first-in-class, orally active, single-molecule that functions as a high-affinity dual-acting antagonist of both endothelin type A (ETA) and angiotensin II subtype 1 (AT1) receptors which are associated with kidney disease progression.

Endothelin I and angiotensin II leads to decline in kidney function by contributing to inflammation and fibrosis in the kidney, changes to the shape of podocytes, podocyte loss, and increased permeability of the glomerular filtration barrier. Endothelin I and angiotensin II are also vasoconstrictive, meaning they cause a narrowing of blood vessels and an increase in pressure in the glomeruli.

Reimbursement of treatments propelling the growth of IgA nephropathy market

Proactively approaching reimbursement can induce a positive impact both during the early stages of product development and well after product launch. The report considers reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with better market access can be a critical business and price strategy.

To assist patients and their healthcare providers who prescribe Tarpeyo, Calliditas has launched a comprehensive patient support program – Tarpeyo Touchpoints. It is a full-service patient and provider support program designed to accelerate and streamline access to Tarpeyo. It utilizes biologics by McKesson’s Pharmacy Elite model integrated hub and exclusive specialty pharmacy under one roof and is staffed by care navigators and a designated rare pod team (nurses, pharmacists, fulfillment, and distribution team).

Sabyasachi Ghosh
Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

What are the Challenges Faced by the IgA Nephropathy Market?

Ignorance towards kidney diseases affecting IgA nephropathy market growth

Although the number of people suffering from kidney diseases is high, the unavailability of exact treatment to cure IgA nephropathy is derailing the progress of the market. In addition, lack of awareness of kidney diseases and ignorance is severely hindering the growth of the market. In certain cases, the time taken for approval for medications is too long. This, in turn, is affecting the growth of the IgA nephropathy market.

Region-Wise Insights

Approval of Therapies and Presence of Drug Manufacturers Boosting Market Growth of IgA Nephropathy Market in North America?

Rising awareness of disease and treatment bolstering the market for IgA nephropathy market in North America

In the coming years, IgAN market is set to change due to the rising awareness of the disease, development of diagnostic techniques, and the favorable environment from regulators, for innovative first-in-class curative drugs, as there were no approved therapies until recently and are likely to expand the market’s size and enable the drug manufacturers to penetrate more into the market.

The companies and academics are working to assess challenges and seek opportunities that could influence IgAN R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition. Major players are involved in developing therapies for IgAN. The launch of emerging therapies will significantly impact the IgAN market. Thus, North America is expected to possess 40% market share for IgA nephropathy market in 2023.

Increasing cases of Kidney Ailments Boosting Growth of IgA Neuropathy Market in Asia Pacific?

Lifestyle changes and sedentary lifestyle contributing to IgA neuropathy market in Asia Pacific

The major factors driving the growth of the market in the Asia region are the rising number of kidney cancer cases and increased R&D expenditure of the pharmaceutical companies. Major countries contributing to kidney cancer cases in Asia are China and Japan. These countries were among the highest cases of kidney cancer worldwide. Furthermore, according to the International Agency for Research on Cancer, in 2018, there were about 148,947 new kidney cancer cases and the mortality was approximately 79,149 cases in Asia.

Furthermore, changes in lifestyle, excessive smoking, increased consumption of alcohol, and a rise in obesity because of sedentary life routines lead to the growing incidence of the disease. Thus, owing to the above factors the Asia-Pacific kidney cancer therapeutics & diagnostics market is expected to significant growth over the forecast period. Owing to the aforementioned reasons, Asia Pacific is expected to possess 35% market share for IgA Neuropathy market in 2023.

MarketNage
Become a MarketNgage Insider

A unified Market Research Subscription Platform, built for today's disparate research needs.

Category-Wise Insights

Favorable Reimbursements Policies Surging Inclination Towards Hospitals?

Initiatives by healthcare organizations spurring dependency on hospitals

Owing to the surge in hospitalization, doctors require diagnostic interpretation for further treatment. Usually, diagnostic centers function in association with hospitals; hence, hospitals have their diagnostic setup. Moreover, the ongoing development of healthcare infrastructure is likely to enhance existing hospital facilities, expanding their services and offerings.

Thus, this expansion may boost the demand for products such as kidney function tests, thereby driving the market. In addition, favorable reimbursement scenarios and an increase in the number of initiatives being undertaken by healthcare organizations globally to promote the use of advanced diagnostic tests are also likely to propel segment growth.

Thus, the hospital’s segment is expected to hold 40% of the market share in 2023 for IgA nephropathy market.

Investments in Urine Test Functioning Increasing Growth of Urine Tests for IgA Nephropathy Market?

Frequent requirement for urine testing increasing dependability on urine tests

The urine tests segment is projected to witness significant a CAGR of 7.5% during the forecast years. One of the most frequently used procedures for assessing renal function is urea quantification. Urine, plasma, and serum urea analyses are crucial clinical tests for detecting renal illness and dysfunction. For the diagnosis of pre-renal, renal, and post-renal uremia, urine tests are frequently performed in conjunction with creatinine determination tests. Furthermore, growing investments in the renal function testing industry are also anticipated to support market expansion.

For instance, in January 2020, Sweden-based Elypta AB raised seed financing of USD 7.0 million to provide the first urine test for renal cancer.

Market Competition

Some of the key companies in the IgA Nephropathy therapeutics market include Calliditas Therapeutics AB, Travere Therapeutics, Inc., Omeros Corporation, Novartis Pharmaceuticals, Chinook Therapeutics, Inc., Vera Therapeutics, Inc., Otsuka Pharmaceutical, and others

  • In January 2022, Calliditas Therapeutics announced the commercial availability and initial sales of Tarpeyo (budesonide), the first and only FDA approved treatment for IgA nephropathy, in the US. It is indicated for reduction of proteinuria in adults with primary IgA nephropathy at risk of rapid disease progression, generally considered a urine protein-to-creatinine ratio (UPCR) ≥1.5g/g.
  • In March 2022, Travere Therapeutics submitted the NDA application for accelerated approval and is expecting the acceptance of application and PUFDA in May 2022.

Report Scope

Report Attribute

Details

Market Value in 2023

US$ 41.24 Billion

Market Value in 2033

US$ 85 Billion

Growth Rate

CAGR of 7.5% from 2023 to 2033

Base Year for Estimation

2022

Historical Data

2017-2022

Forecast Period

2023-2033

Quantitative Units

Revenue in USD Billion and CAGR from 2023-2033

Report Coverage

Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis

Segments Covered

Region

Regions Covered

  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • APEJ
  • Japan
  • Middle East and Africa

Key Countries Profiled

  • U.S
  • Canada
  • Brazil
  • Argentina
  • Germany
  • U.K
  • France
  • Spain
  • Italy
  • Nordics
  • BENELUX
  • Australia & New Zealand
  • China
  • India
  • ASEAN
  • GCC
  • South Africa

Key Companies Profiled

  • Calliditas Therapeutics AB
  • Travere Therapeutics, Inc.
  • Omeros Corporation
  • Novartis Pharmaceuticals
  • Chinook Therapeutics, Inc.
  • Vera Therapeutics, Inc.
  • Otsuka Pharmaceutical
  • Alembic Pharmaceuticals Limited
  • Teva Pharmaceutical Industries Ltd.
  • Johnson & Johnson Private Limited

Customization

Available Upon Request

Key Segments Profiled in the IgA Nephropathy Market Survey

Diagnosis:

  • Iothalamate Clearance Test
  • Kidney Biopsy
  • Blood Tests
  • Urine Tests

Diseases Type:

  • Primary IgA Nephropathy
  • Secondary IgA Nephropathy

Systems:

  • Hematuria
  • Proteinuria
  • Edema
  • Others

Population Type:

  • Pediatrics
  • Adults

Route of Administration:

  • Oral
  • Parenteral
  • Others

Treatment:

  • Medication
  • Statin therapy
  • Omega-3 fatty acids
  • Angiotensin-converting enzyme (ACE) inhibitors
  • Angiotensin receptor blockers (ARBs)
  • Diuretics
  • Immunosuppressants
  • Kidney Transplantation
  • Others

End Users:

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

Region:

  • North America
  • Latin America
  • Europe
  • South Asia & Pacific
  • East Asia
  • Middle East & Africa

Frequently Asked Questions

From 2017-2022, the IgA nephropathy market grew at a CAGR of 4.8%

The global IgA nephropathy market is expected to grow with a 7.5% CAGR during 2023-2033.

As of 2033, the IgA nephropathy market is expected to reach US$ 41.24 Billion

The hospital’s segment is expected to hold 40% of the market share in 2023 for IgA nephropathy market.

The urine tests segment is projected to witness significant a CAGR of 7.5% during the forecast years

North America is expected to possess 40% market share for IgA nephropathy market in 2023.

Asia Pacific IgA nephropathy market size is expected to possess 35% market share in 2023.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018-2022 and Forecast, 2023-2033

    4.1. Historical Market Size Value (US$ Mn) Analysis, 2018-2022

    4.2. Current and Future Market Size Value (US$ Mn) Projections, 2023-2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018-2022 and Forecast 2023-2033, By Diagnosis

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Mn) Analysis By Diagnosis, 2018-2022

    5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Diagnosis, 2023-2033

        5.3.1. Iothalamate Clearance Test

        5.3.2. Kidney Biopsy

        5.3.3. Blood Tests

        5.3.4. Urine Tests

    5.4. Y-o-Y Growth Trend Analysis By Diagnosis, 2018-2022

    5.5. Absolute $ Opportunity Analysis By Diagnosis, 2023-2033

6. Global Market Analysis 2018-2022 and Forecast 2023-2033, By Disease Type

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Mn) Analysis By Disease Type, 2018-2022

    6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Disease Type, 2023-2033

        6.3.1. Primary

        6.3.2. Secondary

    6.4. Y-o-Y Growth Trend Analysis By Disease Type, 2018-2022

    6.5. Absolute $ Opportunity Analysis By Disease Type, 2023-2033

7. Global Market Analysis 2018-2022 and Forecast 2023-2033, By Symptoms

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Mn) Analysis By Symptoms , 2018-2022

    7.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Symptoms , 2023-2033

        7.3.1. Hematuria

        7.3.2. Proteinuria

        7.3.3. Edema

        7.3.4. Others

    7.4. Y-o-Y Growth Trend Analysis By Symptoms , 2018-2022

    7.5. Absolute $ Opportunity Analysis By Symptoms , 2023-2033

8. Global Market Analysis 2018-2022 and Forecast 2023-2033, By Population Type

    8.1. Introduction / Key Findings

    8.2. Historical Market Size Value (US$ Mn) Analysis By Population Type, 2018-2022

    8.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Population Type, 2023-2033

        8.3.1. Pediatrics

        8.3.2. Adults

    8.4. Y-o-Y Growth Trend Analysis By Population Type, 2018-2022

    8.5. Absolute $ Opportunity Analysis By Population Type, 2023-2033

9. Global Market Analysis 2018-2022 and Forecast 2023-2033, By Route of Administration

    9.1. Introduction / Key Findings

    9.2. Historical Market Size Value (US$ Mn) Analysis By Route of Administration, 2018-2022

    9.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Route of Administration, 2023-2033

        9.3.1. Oral

        9.3.2. Parenteral

        9.3.3. Others

    9.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2018-2022

    9.5. Absolute $ Opportunity Analysis By Route of Administration, 2023-2033

10. Global Market Analysis 2018-2022 and Forecast 2023-2033, By Treatment

    10.1. Introduction / Key Findings

    10.2. Historical Market Size Value (US$ Mn) Analysis By Treatment, 2018-2022

    10.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Treatment, 2023-2033

        10.3.1. Medication

        10.3.2. Statin therapy

        10.3.3. Omega-3 fatty acids

        10.3.4. Angiotensin-converting enzyme (ACE) inhibitors

        10.3.5. Angiotensin receptor blockers (ARBs)

        10.3.6. Diuretics

        10.3.7. Immunosuppressants

        10.3.8. Kidney Transplantation

        10.3.9. Others

    10.4. Y-o-Y Growth Trend Analysis By Treatment, 2018-2022

    10.5. Absolute $ Opportunity Analysis By Treatment, 2023-2033

11. Global Market Analysis 2018-2022 and Forecast 2023-2033, By End-Users

    11.1. Introduction / Key Findings

    11.2. Historical Market Size Value (US$ Mn) Analysis By End-Users, 2018-2022

    11.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By End-Users, 2023-2033

        11.3.1. Hospitals

        11.3.2. Specialty Clinics

        11.3.3. Homecare

        11.3.4. Others

    11.4. Y-o-Y Growth Trend Analysis By End-Users, 2018-2022

    11.5. Absolute $ Opportunity Analysis By End-Users, 2023-2033

12. Global Market Analysis 2018-2022 and Forecast 2023-2033, By Region

    12.1. Introduction

    12.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2018-2022

    12.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2023-2033

        12.3.1. North America

        12.3.2. Latin America

        12.3.3. Europe

        12.3.4. South Asia & Pacific

        12.3.5. East Asia

        12.3.6. MEA

    12.4. Market Attractiveness Analysis By Region

13. North America Market Analysis 2018-2022 and Forecast 2023-2033, By Country

    13.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022

    13.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023-2033

        13.2.1. By Country

            13.2.1.1. U.S.

            13.2.1.2. Canada

        13.2.2. By Diagnosis

        13.2.3. By Disease Type

        13.2.4. By Symptoms

        13.2.5. By Population Type

        13.2.6. By Route of Administration

        13.2.7. By Treatment

        13.2.8. By End-Users

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Diagnosis

        13.3.3. By Disease Type

        13.3.4. By Symptoms

        13.3.5. By Population Type

        13.3.6. By Route of Administration

        13.3.7. By Treatment

        13.3.8. By End-Users

    13.4. Key Takeaways

14. Latin America Market Analysis 2018-2022 and Forecast 2023-2033, By Country

    14.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022

    14.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023-2033

        14.2.1. By Country

            14.2.1.1. Brazil

            14.2.1.2. Mexico

            14.2.1.3. Rest of Latin America

        14.2.2. By Diagnosis

        14.2.3. By Disease Type

        14.2.4. By Symptoms

        14.2.5. By Population Type

        14.2.6. By Route of Administration

        14.2.7. By Treatment

        14.2.8. By End-Users

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Diagnosis

        14.3.3. By Disease Type

        14.3.4. By Symptoms

        14.3.5. By Population Type

        14.3.6. By Route of Administration

        14.3.7. By Treatment

        14.3.8. By End-Users

    14.4. Key Takeaways

15. Europe Market Analysis 2018-2022 and Forecast 2023-2033, By Country

    15.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022

    15.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023-2033

        15.2.1. By Country

            15.2.1.1. Germany

            15.2.1.2. U.K.

            15.2.1.3. France

            15.2.1.4. Spain

            15.2.1.5. Italy

            15.2.1.6. Rest of Europe

        15.2.2. By Diagnosis

        15.2.3. By Disease Type

        15.2.4. By Symptoms

        15.2.5. By Population Type

        15.2.6. By Route of Administration

        15.2.7. By Treatment

        15.2.8. By End-Users

    15.3. Market Attractiveness Analysis

        15.3.1. By Country

        15.3.2. By Diagnosis

        15.3.3. By Disease Type

        15.3.4. By Symptoms

        15.3.5. By Population Type

        15.3.6. By Route of Administration

        15.3.7. By Treatment

        15.3.8. By End-Users

    15.4. Key Takeaways

16. South Asia & Pacific Market Analysis 2018-2022 and Forecast 2023-2033, By Country

    16.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022

    16.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023-2033

        16.2.1. By Country

            16.2.1.1. India

            16.2.1.2. Malaysia

            16.2.1.3. Singapore

            16.2.1.4. Thailand

            16.2.1.5. Australia

            16.2.1.6. New Zealand

            16.2.1.7. Rest of South Asia & Pacific

        16.2.2. By Diagnosis

        16.2.3. By Disease Type

        16.2.4. By Symptoms

        16.2.5. By Population Type

        16.2.6. By Route of Administration

        16.2.7. By Treatment

        16.2.8. By End-Users

    16.3. Market Attractiveness Analysis

        16.3.1. By Country

        16.3.2. By Diagnosis

        16.3.3. By Disease Type

        16.3.4. By Symptoms

        16.3.5. By Population Type

        16.3.6. By Route of Administration

        16.3.7. By Treatment

        16.3.8. By End-Users

    16.4. Key Takeaways

17. East Asia Market Analysis 2018-2022 and Forecast 2023-2033, By Country

    17.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022

    17.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023-2033

        17.2.1. By Country

            17.2.1.1. China

            17.2.1.2. Japan

            17.2.1.3. South Korea

        17.2.2. By Diagnosis

        17.2.3. By Disease Type

        17.2.4. By Symptoms

        17.2.5. By Population Type

        17.2.6. By Route of Administration

        17.2.7. By Treatment

        17.2.8. By End-Users

    17.3. Market Attractiveness Analysis

        17.3.1. By Country

        17.3.2. By Diagnosis

        17.3.3. By Disease Type

        17.3.4. By Symptoms

        17.3.5. By Population Type

        17.3.6. By Route of Administration

        17.3.7. By Treatment

        17.3.8. By End-Users

    17.4. Key Takeaways

18. MEA Market Analysis 2018-2022 and Forecast 2023-2033, By Country

    18.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022

    18.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023-2033

        18.2.1. By Country

            18.2.1.1. GCC Countries

            18.2.1.2. South Africa

            18.2.1.3. Israel

            18.2.1.4. Rest of MEA

        18.2.2. By Diagnosis

        18.2.3. By Disease Type

        18.2.4. By Symptoms

        18.2.5. By Population Type

        18.2.6. By Route of Administration

        18.2.7. By Treatment

        18.2.8. By End-Users

    18.3. Market Attractiveness Analysis

        18.3.1. By Country

        18.3.2. By Diagnosis

        18.3.3. By Disease Type

        18.3.4. By Symptoms

        18.3.5. By Population Type

        18.3.6. By Route of Administration

        18.3.7. By Treatment

        18.3.8. By End-Users

    18.4. Key Takeaways

19. Key Countries Market Analysis

    19.1. U.S.

        19.1.1. Pricing Analysis

        19.1.2. Market Share Analysis, 2022

            19.1.2.1. By Diagnosis

            19.1.2.2. By Disease Type

            19.1.2.3. By Symptoms

            19.1.2.4. By Population Type

            19.1.2.5. By Route of Administration

            19.1.2.6. By Treatment

            19.1.2.7. By End-Users

    19.2. Canada

        19.2.1. Pricing Analysis

        19.2.2. Market Share Analysis, 2022

            19.2.2.1. By Diagnosis

            19.2.2.2. By Disease Type

            19.2.2.3. By Symptoms

            19.2.2.4. By Population Type

            19.2.2.5. By Route of Administration

            19.2.2.6. By Treatment

            19.2.2.7. By End-Users

    19.3. Brazil

        19.3.1. Pricing Analysis

        19.3.2. Market Share Analysis, 2022

            19.3.2.1. By Diagnosis

            19.3.2.2. By Disease Type

            19.3.2.3. By Symptoms

            19.3.2.4. By Population Type

            19.3.2.5. By Route of Administration

            19.3.2.6. By Treatment

            19.3.2.7. By End-Users

    19.4. Mexico

        19.4.1. Pricing Analysis

        19.4.2. Market Share Analysis, 2022

            19.4.2.1. By Diagnosis

            19.4.2.2. By Disease Type

            19.4.2.3. By Symptoms

            19.4.2.4. By Population Type

            19.4.2.5. By Route of Administration

            19.4.2.6. By Treatment

            19.4.2.7. By End-Users

    19.5. Germany

        19.5.1. Pricing Analysis

        19.5.2. Market Share Analysis, 2022

            19.5.2.1. By Diagnosis

            19.5.2.2. By Disease Type

            19.5.2.3. By Symptoms

            19.5.2.4. By Population Type

            19.5.2.5. By Route of Administration

            19.5.2.6. By Treatment

            19.5.2.7. By End-Users

    19.6. U.K.

        19.6.1. Pricing Analysis

        19.6.2. Market Share Analysis, 2022

            19.6.2.1. By Diagnosis

            19.6.2.2. By Disease Type

            19.6.2.3. By Symptoms

            19.6.2.4. By Population Type

            19.6.2.5. By Route of Administration

            19.6.2.6. By Treatment

            19.6.2.7. By End-Users

    19.7. France

        19.7.1. Pricing Analysis

        19.7.2. Market Share Analysis, 2022

            19.7.2.1. By Diagnosis

            19.7.2.2. By Disease Type

            19.7.2.3. By Symptoms

            19.7.2.4. By Population Type

            19.7.2.5. By Route of Administration

            19.7.2.6. By Treatment

            19.7.2.7. By End-Users

    19.8. Spain

        19.8.1. Pricing Analysis

        19.8.2. Market Share Analysis, 2022

            19.8.2.1. By Diagnosis

            19.8.2.2. By Disease Type

            19.8.2.3. By Symptoms

            19.8.2.4. By Population Type

            19.8.2.5. By Route of Administration

            19.8.2.6. By Treatment

            19.8.2.7. By End-Users

    19.9. Italy

        19.9.1. Pricing Analysis

        19.9.2. Market Share Analysis, 2022

            19.9.2.1. By Diagnosis

            19.9.2.2. By Disease Type

            19.9.2.3. By Symptoms

            19.9.2.4. By Population Type

            19.9.2.5. By Route of Administration

            19.9.2.6. By Treatment

            19.9.2.7. By End-Users

    19.10. India

        19.10.1. Pricing Analysis

        19.10.2. Market Share Analysis, 2022

            19.10.2.1. By Diagnosis

            19.10.2.2. By Disease Type

            19.10.2.3. By Symptoms

            19.10.2.4. By Population Type

            19.10.2.5. By Route of Administration

            19.10.2.6. By Treatment

            19.10.2.7. By End-Users

    19.11. Malaysia

        19.11.1. Pricing Analysis

        19.11.2. Market Share Analysis, 2022

            19.11.2.1. By Diagnosis

            19.11.2.2. By Disease Type

            19.11.2.3. By Symptoms

            19.11.2.4. By Population Type

            19.11.2.5. By Route of Administration

            19.11.2.6. By Treatment

            19.11.2.7. By End-Users

    19.12. Singapore

        19.12.1. Pricing Analysis

        19.12.2. Market Share Analysis, 2022

            19.12.2.1. By Diagnosis

            19.12.2.2. By Disease Type

            19.12.2.3. By Symptoms

            19.12.2.4. By Population Type

            19.12.2.5. By Route of Administration

            19.12.2.6. By Treatment

            19.12.2.7. By End-Users

    19.13. Thailand

        19.13.1. Pricing Analysis

        19.13.2. Market Share Analysis, 2022

            19.13.2.1. By Diagnosis

            19.13.2.2. By Disease Type

            19.13.2.3. By Symptoms

            19.13.2.4. By Population Type

            19.13.2.5. By Route of Administration

            19.13.2.6. By Treatment

            19.13.2.7. By End-Users

    19.14. Australia

        19.14.1. Pricing Analysis

        19.14.2. Market Share Analysis, 2022

            19.14.2.1. By Diagnosis

            19.14.2.2. By Disease Type

            19.14.2.3. By Symptoms

            19.14.2.4. By Population Type

            19.14.2.5. By Route of Administration

            19.14.2.6. By Treatment

            19.14.2.7. By End-Users

    19.15. New Zealand

        19.15.1. Pricing Analysis

        19.15.2. Market Share Analysis, 2022

            19.15.2.1. By Diagnosis

            19.15.2.2. By Disease Type

            19.15.2.3. By Symptoms

            19.15.2.4. By Population Type

            19.15.2.5. By Route of Administration

            19.15.2.6. By Treatment

            19.15.2.7. By End-Users

    19.16. China

        19.16.1. Pricing Analysis

        19.16.2. Market Share Analysis, 2022

            19.16.2.1. By Diagnosis

            19.16.2.2. By Disease Type

            19.16.2.3. By Symptoms

            19.16.2.4. By Population Type

            19.16.2.5. By Route of Administration

            19.16.2.6. By Treatment

            19.16.2.7. By End-Users

    19.17. Japan

        19.17.1. Pricing Analysis

        19.17.2. Market Share Analysis, 2022

            19.17.2.1. By Diagnosis

            19.17.2.2. By Disease Type

            19.17.2.3. By Symptoms

            19.17.2.4. By Population Type

            19.17.2.5. By Route of Administration

            19.17.2.6. By Treatment

            19.17.2.7. By End-Users

    19.18. South Korea

        19.18.1. Pricing Analysis

        19.18.2. Market Share Analysis, 2022

            19.18.2.1. By Diagnosis

            19.18.2.2. By Disease Type

            19.18.2.3. By Symptoms

            19.18.2.4. By Population Type

            19.18.2.5. By Route of Administration

            19.18.2.6. By Treatment

            19.18.2.7. By End-Users

    19.19. GCC Countries

        19.19.1. Pricing Analysis

        19.19.2. Market Share Analysis, 2022

            19.19.2.1. By Diagnosis

            19.19.2.2. By Disease Type

            19.19.2.3. By Symptoms

            19.19.2.4. By Population Type

            19.19.2.5. By Route of Administration

            19.19.2.6. By Treatment

            19.19.2.7. By End-Users

    19.20. South Africa

        19.20.1. Pricing Analysis

        19.20.2. Market Share Analysis, 2022

            19.20.2.1. By Diagnosis

            19.20.2.2. By Disease Type

            19.20.2.3. By Symptoms

            19.20.2.4. By Population Type

            19.20.2.5. By Route of Administration

            19.20.2.6. By Treatment

            19.20.2.7. By End-Users

    19.21. Israel

        19.21.1. Pricing Analysis

        19.21.2. Market Share Analysis, 2022

            19.21.2.1. By Diagnosis

            19.21.2.2. By Disease Type

            19.21.2.3. By Symptoms

            19.21.2.4. By Population Type

            19.21.2.5. By Route of Administration

            19.21.2.6. By Treatment

            19.21.2.7. By End-Users

20. Market Structure Analysis

    20.1. Competition Dashboard

    20.2. Competition Benchmarking

    20.3. Market Share Analysis of Top Players

        20.3.1. By Regional

        20.3.2. By Diagnosis

        20.3.3. By Disease Type

        20.3.4. By Symptoms

        20.3.5. By Population Type

        20.3.6. By Route of Administration

        20.3.7. By Treatment

        20.3.8. By End-Users

21. Competition Analysis

    21.1. Competition Deep Dive

        21.1.1. Calliditas Therapeutics AB

            21.1.1.1. Overview

            21.1.1.2. Product Portfolio

            21.1.1.3. Profitability by Market Segments

            21.1.1.4. Sales Footprint

            21.1.1.5. Strategy Overview

                21.1.1.5.1. Marketing Strategy

        21.1.2. Travere Therapeutics, Inc.

            21.1.2.1. Overview

            21.1.2.2. Product Portfolio

            21.1.2.3. Profitability by Market Segments

            21.1.2.4. Sales Footprint

            21.1.2.5. Strategy Overview

                21.1.2.5.1. Marketing Strategy

        21.1.3. Omeros Corporation

            21.1.3.1. Overview

            21.1.3.2. Product Portfolio

            21.1.3.3. Profitability by Market Segments

            21.1.3.4. Sales Footprint

            21.1.3.5. Strategy Overview

                21.1.3.5.1. Marketing Strategy

        21.1.4. Novartis Pharmaceuticals

            21.1.4.1. Overview

            21.1.4.2. Product Portfolio

            21.1.4.3. Profitability by Market Segments

            21.1.4.4. Sales Footprint

            21.1.4.5. Strategy Overview

                21.1.4.5.1. Marketing Strategy

        21.1.5. Chinook Therapeutics, Inc.

            21.1.5.1. Overview

            21.1.5.2. Product Portfolio

            21.1.5.3. Profitability by Market Segments

            21.1.5.4. Sales Footprint

            21.1.5.5. Strategy Overview

                21.1.5.5.1. Marketing Strategy

        21.1.6. Vera Therapeutics, Inc.

            21.1.6.1. Overview

            21.1.6.2. Product Portfolio

            21.1.6.3. Profitability by Market Segments

            21.1.6.4. Sales Footprint

            21.1.6.5. Strategy Overview

                21.1.6.5.1. Marketing Strategy

        21.1.7. Otsuka Pharmaceutical

            21.1.7.1. Overview

            21.1.7.2. Product Portfolio

            21.1.7.3. Profitability by Market Segments

            21.1.7.4. Sales Footprint

            21.1.7.5. Strategy Overview

                21.1.7.5.1. Marketing Strategy

        21.1.8. Alembic Pharmaceuticals Limited

            21.1.8.1. Overview

            21.1.8.2. Product Portfolio

            21.1.8.3. Profitability by Market Segments

            21.1.8.4. Sales Footprint

            21.1.8.5. Strategy Overview

                21.1.8.5.1. Marketing Strategy

        21.1.9. Teva Pharmaceutical Industries Ltd.

            21.1.9.1. Overview

            21.1.9.2. Product Portfolio

            21.1.9.3. Profitability by Market Segments

            21.1.9.4. Sales Footprint

            21.1.9.5. Strategy Overview

                21.1.9.5.1. Marketing Strategy

        21.1.10. Johnson & Johnson Private Limited

            21.1.10.1. Overview

            21.1.10.2. Product Portfolio

            21.1.10.3. Profitability by Market Segments

            21.1.10.4. Sales Footprint

            21.1.10.5. Strategy Overview

                21.1.10.5.1. Marketing Strategy

22. Assumptions & Acronyms Used

23. Research Methodology

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

Table 1: Global Market Value (US$ Mn) Forecast by Region, 2018-2033

Table 2: Global Market Value (US$ Mn) Forecast by Diagnosis, 2018-2033

Table 3: Global Market Value (US$ Mn) Forecast by Disease Type, 2018-2033

Table 4: Global Market Value (US$ Mn) Forecast by Symptoms , 2018-2033

Table 5: Global Market Value (US$ Mn) Forecast by Population Type, 2018-2033

Table 6: Global Market Value (US$ Mn) Forecast by Route of Administration, 2018-2033

Table 7: Global Market Value (US$ Mn) Forecast by Treatment, 2018-2033

Table 8: Global Market Value (US$ Mn) Forecast by End-Users, 2018-2033

Table 9: North America Market Value (US$ Mn) Forecast by Country, 2018-2033

Table 10: North America Market Value (US$ Mn) Forecast by Diagnosis, 2018-2033

Table 11: North America Market Value (US$ Mn) Forecast by Disease Type, 2018-2033

Table 12: North America Market Value (US$ Mn) Forecast by Symptoms , 2018-2033

Table 13: North America Market Value (US$ Mn) Forecast by Population Type, 2018-2033

Table 14: North America Market Value (US$ Mn) Forecast by Route of Administration, 2018-2033

Table 15: North America Market Value (US$ Mn) Forecast by Treatment, 2018-2033

Table 16: North America Market Value (US$ Mn) Forecast by End-Users, 2018-2033

Table 17: Latin America Market Value (US$ Mn) Forecast by Country, 2018-2033

Table 18: Latin America Market Value (US$ Mn) Forecast by Diagnosis, 2018-2033

Table 19: Latin America Market Value (US$ Mn) Forecast by Disease Type, 2018-2033

Table 20: Latin America Market Value (US$ Mn) Forecast by Symptoms , 2018-2033

Table 21: Latin America Market Value (US$ Mn) Forecast by Population Type, 2018-2033

Table 22: Latin America Market Value (US$ Mn) Forecast by Route of Administration, 2018-2033

Table 23: Latin America Market Value (US$ Mn) Forecast by Treatment, 2018-2033

Table 24: Latin America Market Value (US$ Mn) Forecast by End-Users, 2018-2033

Table 25: Europe Market Value (US$ Mn) Forecast by Country, 2018-2033

Table 26: Europe Market Value (US$ Mn) Forecast by Diagnosis, 2018-2033

Table 27: Europe Market Value (US$ Mn) Forecast by Disease Type, 2018-2033

Table 28: Europe Market Value (US$ Mn) Forecast by Symptoms , 2018-2033

Table 29: Europe Market Value (US$ Mn) Forecast by Population Type, 2018-2033

Table 30: Europe Market Value (US$ Mn) Forecast by Route of Administration, 2018-2033

Table 31: Europe Market Value (US$ Mn) Forecast by Treatment, 2018-2033

Table 32: Europe Market Value (US$ Mn) Forecast by End-Users, 2018-2033

Table 33: South Asia & Pacific Market Value (US$ Mn) Forecast by Country, 2018-2033

Table 34: South Asia & Pacific Market Value (US$ Mn) Forecast by Diagnosis, 2018-2033

Table 35: South Asia & Pacific Market Value (US$ Mn) Forecast by Disease Type, 2018-2033

Table 36: South Asia & Pacific Market Value (US$ Mn) Forecast by Symptoms , 2018-2033

Table 37: South Asia & Pacific Market Value (US$ Mn) Forecast by Population Type, 2018-2033

Table 38: South Asia & Pacific Market Value (US$ Mn) Forecast by Route of Administration, 2018-2033

Table 39: South Asia & Pacific Market Value (US$ Mn) Forecast by Treatment, 2018-2033

Table 40: South Asia & Pacific Market Value (US$ Mn) Forecast by End-Users, 2018-2033

Table 41: East Asia Market Value (US$ Mn) Forecast by Country, 2018-2033

Table 42: East Asia Market Value (US$ Mn) Forecast by Diagnosis, 2018-2033

Table 43: East Asia Market Value (US$ Mn) Forecast by Disease Type, 2018-2033

Table 44: East Asia Market Value (US$ Mn) Forecast by Symptoms , 2018-2033

Table 45: East Asia Market Value (US$ Mn) Forecast by Population Type, 2018-2033

Table 46: East Asia Market Value (US$ Mn) Forecast by Route of Administration, 2018-2033

Table 47: East Asia Market Value (US$ Mn) Forecast by Treatment, 2018-2033

Table 48: East Asia Market Value (US$ Mn) Forecast by End-Users, 2018-2033

Table 49: MEA Market Value (US$ Mn) Forecast by Country, 2018-2033

Table 50: MEA Market Value (US$ Mn) Forecast by Diagnosis, 2018-2033

Table 51: MEA Market Value (US$ Mn) Forecast by Disease Type, 2018-2033

Table 52: MEA Market Value (US$ Mn) Forecast by Symptoms , 2018-2033

Table 53: MEA Market Value (US$ Mn) Forecast by Population Type, 2018-2033

Table 54: MEA Market Value (US$ Mn) Forecast by Route of Administration, 2018-2033

Table 55: MEA Market Value (US$ Mn) Forecast by Treatment, 2018-2033

Table 56: MEA Market Value (US$ Mn) Forecast by End-Users, 2018-2033

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

Figure 1: Global Market Value (US$ Mn) by Diagnosis, 2023-2033

Figure 2: Global Market Value (US$ Mn) by Disease Type, 2023-2033

Figure 3: Global Market Value (US$ Mn) by Symptoms , 2023-2033

Figure 4: Global Market Value (US$ Mn) by Population Type, 2023-2033

Figure 5: Global Market Value (US$ Mn) by Route of Administration, 2023-2033

Figure 6: Global Market Value (US$ Mn) by Treatment, 2023-2033

Figure 7: Global Market Value (US$ Mn) by End-Users, 2023-2033

Figure 8: Global Market Value (US$ Mn) by Region, 2023-2033

Figure 9: Global Market Value (US$ Mn) Analysis by Region, 2018-2033

Figure 10: Global Market Value Share (%) and BPS Analysis by Region, 2023-2033

Figure 11: Global Market Y-o-Y Growth (%) Projections by Region, 2023-2033

Figure 12: Global Market Value (US$ Mn) Analysis by Diagnosis, 2018-2033

Figure 13: Global Market Value Share (%) and BPS Analysis by Diagnosis, 2023-2033

Figure 14: Global Market Y-o-Y Growth (%) Projections by Diagnosis, 2023-2033

Figure 15: Global Market Value (US$ Mn) Analysis by Disease Type, 2018-2033

Figure 16: Global Market Value Share (%) and BPS Analysis by Disease Type, 2023-2033

Figure 17: Global Market Y-o-Y Growth (%) Projections by Disease Type, 2023-2033

Figure 18: Global Market Value (US$ Mn) Analysis by Symptoms , 2018-2033

Figure 19: Global Market Value Share (%) and BPS Analysis by Symptoms , 2023-2033

Figure 20: Global Market Y-o-Y Growth (%) Projections by Symptoms , 2023-2033

Figure 21: Global Market Value (US$ Mn) Analysis by Population Type, 2018-2033

Figure 22: Global Market Value Share (%) and BPS Analysis by Population Type, 2023-2033

Figure 23: Global Market Y-o-Y Growth (%) Projections by Population Type, 2023-2033

Figure 24: Global Market Value (US$ Mn) Analysis by Route of Administration, 2018-2033

Figure 25: Global Market Value Share (%) and BPS Analysis by Route of Administration, 2023-2033

Figure 26: Global Market Y-o-Y Growth (%) Projections by Route of Administration, 2023-2033

Figure 27: Global Market Value (US$ Mn) Analysis by Treatment, 2018-2033

Figure 28: Global Market Value Share (%) and BPS Analysis by Treatment, 2023-2033

Figure 29: Global Market Y-o-Y Growth (%) Projections by Treatment, 2023-2033

Figure 30: Global Market Value (US$ Mn) Analysis by End-Users, 2018-2033

Figure 31: Global Market Value Share (%) and BPS Analysis by End-Users, 2023-2033

Figure 32: Global Market Y-o-Y Growth (%) Projections by End-Users, 2023-2033

Figure 33: Global Market Attractiveness by Diagnosis, 2023-2033

Figure 34: Global Market Attractiveness by Disease Type, 2023-2033

Figure 35: Global Market Attractiveness by Symptoms , 2023-2033

Figure 36: Global Market Attractiveness by Population Type, 2023-2033

Figure 37: Global Market Attractiveness by Route of Administration, 2023-2033

Figure 38: Global Market Attractiveness by Treatment, 2023-2033

Figure 39: Global Market Attractiveness by End-Users, 2023-2033

Figure 40: Global Market Attractiveness by Region, 2023-2033

Figure 41: North America Market Value (US$ Mn) by Diagnosis, 2023-2033

Figure 42: North America Market Value (US$ Mn) by Disease Type, 2023-2033

Figure 43: North America Market Value (US$ Mn) by Symptoms , 2023-2033

Figure 44: North America Market Value (US$ Mn) by Population Type, 2023-2033

Figure 45: North America Market Value (US$ Mn) by Route of Administration, 2023-2033

Figure 46: North America Market Value (US$ Mn) by Treatment, 2023-2033

Figure 47: North America Market Value (US$ Mn) by End-Users, 2023-2033

Figure 48: North America Market Value (US$ Mn) by Country, 2023-2033

Figure 49: North America Market Value (US$ Mn) Analysis by Country, 2018-2033

Figure 50: North America Market Value Share (%) and BPS Analysis by Country, 2023-2033

Figure 51: North America Market Y-o-Y Growth (%) Projections by Country, 2023-2033

Figure 52: North America Market Value (US$ Mn) Analysis by Diagnosis, 2018-2033

Figure 53: North America Market Value Share (%) and BPS Analysis by Diagnosis, 2023-2033

Figure 54: North America Market Y-o-Y Growth (%) Projections by Diagnosis, 2023-2033

Figure 55: North America Market Value (US$ Mn) Analysis by Disease Type, 2018-2033

Figure 56: North America Market Value Share (%) and BPS Analysis by Disease Type, 2023-2033

Figure 57: North America Market Y-o-Y Growth (%) Projections by Disease Type, 2023-2033

Figure 58: North America Market Value (US$ Mn) Analysis by Symptoms , 2018-2033

Figure 59: North America Market Value Share (%) and BPS Analysis by Symptoms , 2023-2033

Figure 60: North America Market Y-o-Y Growth (%) Projections by Symptoms , 2023-2033

Figure 61: North America Market Value (US$ Mn) Analysis by Population Type, 2018-2033

Figure 62: North America Market Value Share (%) and BPS Analysis by Population Type, 2023-2033

Figure 63: North America Market Y-o-Y Growth (%) Projections by Population Type, 2023-2033

Figure 64: North America Market Value (US$ Mn) Analysis by Route of Administration, 2018-2033

Figure 65: North America Market Value Share (%) and BPS Analysis by Route of Administration, 2023-2033

Figure 66: North America Market Y-o-Y Growth (%) Projections by Route of Administration, 2023-2033

Figure 67: North America Market Value (US$ Mn) Analysis by Treatment, 2018-2033

Figure 68: North America Market Value Share (%) and BPS Analysis by Treatment, 2023-2033

Figure 69: North America Market Y-o-Y Growth (%) Projections by Treatment, 2023-2033

Figure 70: North America Market Value (US$ Mn) Analysis by End-Users, 2018-2033

Figure 71: North America Market Value Share (%) and BPS Analysis by End-Users, 2023-2033

Figure 72: North America Market Y-o-Y Growth (%) Projections by End-Users, 2023-2033

Figure 73: North America Market Attractiveness by Diagnosis, 2023-2033

Figure 74: North America Market Attractiveness by Disease Type, 2023-2033

Figure 75: North America Market Attractiveness by Symptoms , 2023-2033

Figure 76: North America Market Attractiveness by Population Type, 2023-2033

Figure 77: North America Market Attractiveness by Route of Administration, 2023-2033

Figure 78: North America Market Attractiveness by Treatment, 2023-2033

Figure 79: North America Market Attractiveness by End-Users, 2023-2033

Figure 80: North America Market Attractiveness by Country, 2023-2033

Figure 81: Latin America Market Value (US$ Mn) by Diagnosis, 2023-2033

Figure 82: Latin America Market Value (US$ Mn) by Disease Type, 2023-2033

Figure 83: Latin America Market Value (US$ Mn) by Symptoms , 2023-2033

Figure 84: Latin America Market Value (US$ Mn) by Population Type, 2023-2033

Figure 85: Latin America Market Value (US$ Mn) by Route of Administration, 2023-2033

Figure 86: Latin America Market Value (US$ Mn) by Treatment, 2023-2033

Figure 87: Latin America Market Value (US$ Mn) by End-Users, 2023-2033

Figure 88: Latin America Market Value (US$ Mn) by Country, 2023-2033

Figure 89: Latin America Market Value (US$ Mn) Analysis by Country, 2018-2033

Figure 90: Latin America Market Value Share (%) and BPS Analysis by Country, 2023-2033

Figure 91: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023-2033

Figure 92: Latin America Market Value (US$ Mn) Analysis by Diagnosis, 2018-2033

Figure 93: Latin America Market Value Share (%) and BPS Analysis by Diagnosis, 2023-2033

Figure 94: Latin America Market Y-o-Y Growth (%) Projections by Diagnosis, 2023-2033

Figure 95: Latin America Market Value (US$ Mn) Analysis by Disease Type, 2018-2033

Figure 96: Latin America Market Value Share (%) and BPS Analysis by Disease Type, 2023-2033

Figure 97: Latin America Market Y-o-Y Growth (%) Projections by Disease Type, 2023-2033

Figure 98: Latin America Market Value (US$ Mn) Analysis by Symptoms , 2018-2033

Figure 99: Latin America Market Value Share (%) and BPS Analysis by Symptoms , 2023-2033

Figure 100: Latin America Market Y-o-Y Growth (%) Projections by Symptoms , 2023-2033

Figure 101: Latin America Market Value (US$ Mn) Analysis by Population Type, 2018-2033

Figure 102: Latin America Market Value Share (%) and BPS Analysis by Population Type, 2023-2033

Figure 103: Latin America Market Y-o-Y Growth (%) Projections by Population Type, 2023-2033

Figure 104: Latin America Market Value (US$ Mn) Analysis by Route of Administration, 2018-2033

Figure 105: Latin America Market Value Share (%) and BPS Analysis by Route of Administration, 2023-2033

Figure 106: Latin America Market Y-o-Y Growth (%) Projections by Route of Administration, 2023-2033

Figure 107: Latin America Market Value (US$ Mn) Analysis by Treatment, 2018-2033

Figure 108: Latin America Market Value Share (%) and BPS Analysis by Treatment, 2023-2033

Figure 109: Latin America Market Y-o-Y Growth (%) Projections by Treatment, 2023-2033

Figure 110: Latin America Market Value (US$ Mn) Analysis by End-Users, 2018-2033

Figure 111: Latin America Market Value Share (%) and BPS Analysis by End-Users, 2023-2033

Figure 112: Latin America Market Y-o-Y Growth (%) Projections by End-Users, 2023-2033

Figure 113: Latin America Market Attractiveness by Diagnosis, 2023-2033

Figure 114: Latin America Market Attractiveness by Disease Type, 2023-2033

Figure 115: Latin America Market Attractiveness by Symptoms , 2023-2033

Figure 116: Latin America Market Attractiveness by Population Type, 2023-2033

Figure 117: Latin America Market Attractiveness by Route of Administration, 2023-2033

Figure 118: Latin America Market Attractiveness by Treatment, 2023-2033

Figure 119: Latin America Market Attractiveness by End-Users, 2023-2033

Figure 120: Latin America Market Attractiveness by Country, 2023-2033

Figure 121: Europe Market Value (US$ Mn) by Diagnosis, 2023-2033

Figure 122: Europe Market Value (US$ Mn) by Disease Type, 2023-2033

Figure 123: Europe Market Value (US$ Mn) by Symptoms , 2023-2033

Figure 124: Europe Market Value (US$ Mn) by Population Type, 2023-2033

Figure 125: Europe Market Value (US$ Mn) by Route of Administration, 2023-2033

Figure 126: Europe Market Value (US$ Mn) by Treatment, 2023-2033

Figure 127: Europe Market Value (US$ Mn) by End-Users, 2023-2033

Figure 128: Europe Market Value (US$ Mn) by Country, 2023-2033

Figure 129: Europe Market Value (US$ Mn) Analysis by Country, 2018-2033

Figure 130: Europe Market Value Share (%) and BPS Analysis by Country, 2023-2033

Figure 131: Europe Market Y-o-Y Growth (%) Projections by Country, 2023-2033

Figure 132: Europe Market Value (US$ Mn) Analysis by Diagnosis, 2018-2033

Figure 133: Europe Market Value Share (%) and BPS Analysis by Diagnosis, 2023-2033

Figure 134: Europe Market Y-o-Y Growth (%) Projections by Diagnosis, 2023-2033

Figure 135: Europe Market Value (US$ Mn) Analysis by Disease Type, 2018-2033

Figure 136: Europe Market Value Share (%) and BPS Analysis by Disease Type, 2023-2033

Figure 137: Europe Market Y-o-Y Growth (%) Projections by Disease Type, 2023-2033

Figure 138: Europe Market Value (US$ Mn) Analysis by Symptoms , 2018-2033

Figure 139: Europe Market Value Share (%) and BPS Analysis by Symptoms , 2023-2033

Figure 140: Europe Market Y-o-Y Growth (%) Projections by Symptoms , 2023-2033

Figure 141: Europe Market Value (US$ Mn) Analysis by Population Type, 2018-2033

Figure 142: Europe Market Value Share (%) and BPS Analysis by Population Type, 2023-2033

Figure 143: Europe Market Y-o-Y Growth (%) Projections by Population Type, 2023-2033

Figure 144: Europe Market Value (US$ Mn) Analysis by Route of Administration, 2018-2033

Figure 145: Europe Market Value Share (%) and BPS Analysis by Route of Administration, 2023-2033

Figure 146: Europe Market Y-o-Y Growth (%) Projections by Route of Administration, 2023-2033

Figure 147: Europe Market Value (US$ Mn) Analysis by Treatment, 2018-2033

Figure 148: Europe Market Value Share (%) and BPS Analysis by Treatment, 2023-2033

Figure 149: Europe Market Y-o-Y Growth (%) Projections by Treatment, 2023-2033

Figure 150: Europe Market Value (US$ Mn) Analysis by End-Users, 2018-2033

Figure 151: Europe Market Value Share (%) and BPS Analysis by End-Users, 2023-2033

Figure 152: Europe Market Y-o-Y Growth (%) Projections by End-Users, 2023-2033

Figure 153: Europe Market Attractiveness by Diagnosis, 2023-2033

Figure 154: Europe Market Attractiveness by Disease Type, 2023-2033

Figure 155: Europe Market Attractiveness by Symptoms , 2023-2033

Figure 156: Europe Market Attractiveness by Population Type, 2023-2033

Figure 157: Europe Market Attractiveness by Route of Administration, 2023-2033

Figure 158: Europe Market Attractiveness by Treatment, 2023-2033

Figure 159: Europe Market Attractiveness by End-Users, 2023-2033

Figure 160: Europe Market Attractiveness by Country, 2023-2033

Figure 161: South Asia & Pacific Market Value (US$ Mn) by Diagnosis, 2023-2033

Figure 162: South Asia & Pacific Market Value (US$ Mn) by Disease Type, 2023-2033

Figure 163: South Asia & Pacific Market Value (US$ Mn) by Symptoms , 2023-2033

Figure 164: South Asia & Pacific Market Value (US$ Mn) by Population Type, 2023-2033

Figure 165: South Asia & Pacific Market Value (US$ Mn) by Route of Administration, 2023-2033

Figure 166: South Asia & Pacific Market Value (US$ Mn) by Treatment, 2023-2033

Figure 167: South Asia & Pacific Market Value (US$ Mn) by End-Users, 2023-2033

Figure 168: South Asia & Pacific Market Value (US$ Mn) by Country, 2023-2033

Figure 169: South Asia & Pacific Market Value (US$ Mn) Analysis by Country, 2018-2033

Figure 170: South Asia & Pacific Market Value Share (%) and BPS Analysis by Country, 2023-2033

Figure 171: South Asia & Pacific Market Y-o-Y Growth (%) Projections by Country, 2023-2033

Figure 172: South Asia & Pacific Market Value (US$ Mn) Analysis by Diagnosis, 2018-2033

Figure 173: South Asia & Pacific Market Value Share (%) and BPS Analysis by Diagnosis, 2023-2033

Figure 174: South Asia & Pacific Market Y-o-Y Growth (%) Projections by Diagnosis, 2023-2033

Figure 175: South Asia & Pacific Market Value (US$ Mn) Analysis by Disease Type, 2018-2033

Figure 176: South Asia & Pacific Market Value Share (%) and BPS Analysis by Disease Type, 2023-2033

Figure 177: South Asia & Pacific Market Y-o-Y Growth (%) Projections by Disease Type, 2023-2033

Figure 178: South Asia & Pacific Market Value (US$ Mn) Analysis by Symptoms , 2018-2033

Figure 179: South Asia & Pacific Market Value Share (%) and BPS Analysis by Symptoms , 2023-2033

Figure 180: South Asia & Pacific Market Y-o-Y Growth (%) Projections by Symptoms , 2023-2033

Figure 181: South Asia & Pacific Market Value (US$ Mn) Analysis by Population Type, 2018-2033

Figure 182: South Asia & Pacific Market Value Share (%) and BPS Analysis by Population Type, 2023-2033

Figure 183: South Asia & Pacific Market Y-o-Y Growth (%) Projections by Population Type, 2023-2033

Figure 184: South Asia & Pacific Market Value (US$ Mn) Analysis by Route of Administration, 2018-2033

Figure 185: South Asia & Pacific Market Value Share (%) and BPS Analysis by Route of Administration, 2023-2033

Figure 186: South Asia & Pacific Market Y-o-Y Growth (%) Projections by Route of Administration, 2023-2033

Figure 187: South Asia & Pacific Market Value (US$ Mn) Analysis by Treatment, 2018-2033

Figure 188: South Asia & Pacific Market Value Share (%) and BPS Analysis by Treatment, 2023-2033

Figure 189: South Asia & Pacific Market Y-o-Y Growth (%) Projections by Treatment, 2023-2033

Figure 190: South Asia & Pacific Market Value (US$ Mn) Analysis by End-Users, 2018-2033

Figure 191: South Asia & Pacific Market Value Share (%) and BPS Analysis by End-Users, 2023-2033

Figure 192: South Asia & Pacific Market Y-o-Y Growth (%) Projections by End-Users, 2023-2033

Figure 193: South Asia & Pacific Market Attractiveness by Diagnosis, 2023-2033

Figure 194: South Asia & Pacific Market Attractiveness by Disease Type, 2023-2033

Figure 195: South Asia & Pacific Market Attractiveness by Symptoms , 2023-2033

Figure 196: South Asia & Pacific Market Attractiveness by Population Type, 2023-2033

Figure 197: South Asia & Pacific Market Attractiveness by Route of Administration, 2023-2033

Figure 198: South Asia & Pacific Market Attractiveness by Treatment, 2023-2033

Figure 199: South Asia & Pacific Market Attractiveness by End-Users, 2023-2033

Figure 200: South Asia & Pacific Market Attractiveness by Country, 2023-2033

Figure 201: East Asia Market Value (US$ Mn) by Diagnosis, 2023-2033

Figure 202: East Asia Market Value (US$ Mn) by Disease Type, 2023-2033

Figure 203: East Asia Market Value (US$ Mn) by Symptoms , 2023-2033

Figure 204: East Asia Market Value (US$ Mn) by Population Type, 2023-2033

Figure 205: East Asia Market Value (US$ Mn) by Route of Administration, 2023-2033

Figure 206: East Asia Market Value (US$ Mn) by Treatment, 2023-2033

Figure 207: East Asia Market Value (US$ Mn) by End-Users, 2023-2033

Figure 208: East Asia Market Value (US$ Mn) by Country, 2023-2033

Figure 209: East Asia Market Value (US$ Mn) Analysis by Country, 2018-2033

Figure 210: East Asia Market Value Share (%) and BPS Analysis by Country, 2023-2033

Figure 211: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023-2033

Figure 212: East Asia Market Value (US$ Mn) Analysis by Diagnosis, 2018-2033

Figure 213: East Asia Market Value Share (%) and BPS Analysis by Diagnosis, 2023-2033

Figure 214: East Asia Market Y-o-Y Growth (%) Projections by Diagnosis, 2023-2033

Figure 215: East Asia Market Value (US$ Mn) Analysis by Disease Type, 2018-2033

Figure 216: East Asia Market Value Share (%) and BPS Analysis by Disease Type, 2023-2033

Figure 217: East Asia Market Y-o-Y Growth (%) Projections by Disease Type, 2023-2033

Figure 218: East Asia Market Value (US$ Mn) Analysis by Symptoms , 2018-2033

Figure 219: East Asia Market Value Share (%) and BPS Analysis by Symptoms , 2023-2033

Figure 220: East Asia Market Y-o-Y Growth (%) Projections by Symptoms , 2023-2033

Figure 221: East Asia Market Value (US$ Mn) Analysis by Population Type, 2018-2033

Figure 222: East Asia Market Value Share (%) and BPS Analysis by Population Type, 2023-2033

Figure 223: East Asia Market Y-o-Y Growth (%) Projections by Population Type, 2023-2033

Figure 224: East Asia Market Value (US$ Mn) Analysis by Route of Administration, 2018-2033

Figure 225: East Asia Market Value Share (%) and BPS Analysis by Route of Administration, 2023-2033

Figure 226: East Asia Market Y-o-Y Growth (%) Projections by Route of Administration, 2023-2033

Figure 227: East Asia Market Value (US$ Mn) Analysis by Treatment, 2018-2033

Figure 228: East Asia Market Value Share (%) and BPS Analysis by Treatment, 2023-2033

Figure 229: East Asia Market Y-o-Y Growth (%) Projections by Treatment, 2023-2033

Figure 230: East Asia Market Value (US$ Mn) Analysis by End-Users, 2018-2033

Figure 231: East Asia Market Value Share (%) and BPS Analysis by End-Users, 2023-2033

Figure 232: East Asia Market Y-o-Y Growth (%) Projections by End-Users, 2023-2033

Figure 233: East Asia Market Attractiveness by Diagnosis, 2023-2033

Figure 234: East Asia Market Attractiveness by Disease Type, 2023-2033

Figure 235: East Asia Market Attractiveness by Symptoms , 2023-2033

Figure 236: East Asia Market Attractiveness by Population Type, 2023-2033

Figure 237: East Asia Market Attractiveness by Route of Administration, 2023-2033

Figure 238: East Asia Market Attractiveness by Treatment, 2023-2033

Figure 239: East Asia Market Attractiveness by End-Users, 2023-2033

Figure 240: East Asia Market Attractiveness by Country, 2023-2033

Figure 241: MEA Market Value (US$ Mn) by Diagnosis, 2023-2033

Figure 242: MEA Market Value (US$ Mn) by Disease Type, 2023-2033

Figure 243: MEA Market Value (US$ Mn) by Symptoms , 2023-2033

Figure 244: MEA Market Value (US$ Mn) by Population Type, 2023-2033

Figure 245: MEA Market Value (US$ Mn) by Route of Administration, 2023-2033

Figure 246: MEA Market Value (US$ Mn) by Treatment, 2023-2033

Figure 247: MEA Market Value (US$ Mn) by End-Users, 2023-2033

Figure 248: MEA Market Value (US$ Mn) by Country, 2023-2033

Figure 249: MEA Market Value (US$ Mn) Analysis by Country, 2018-2033

Figure 250: MEA Market Value Share (%) and BPS Analysis by Country, 2023-2033

Figure 251: MEA Market Y-o-Y Growth (%) Projections by Country, 2023-2033

Figure 252: MEA Market Value (US$ Mn) Analysis by Diagnosis, 2018-2033

Figure 253: MEA Market Value Share (%) and BPS Analysis by Diagnosis, 2023-2033

Figure 254: MEA Market Y-o-Y Growth (%) Projections by Diagnosis, 2023-2033

Figure 255: MEA Market Value (US$ Mn) Analysis by Disease Type, 2018-2033

Figure 256: MEA Market Value Share (%) and BPS Analysis by Disease Type, 2023-2033

Figure 257: MEA Market Y-o-Y Growth (%) Projections by Disease Type, 2023-2033

Figure 258: MEA Market Value (US$ Mn) Analysis by Symptoms , 2018-2033

Figure 259: MEA Market Value Share (%) and BPS Analysis by Symptoms , 2023-2033

Figure 260: MEA Market Y-o-Y Growth (%) Projections by Symptoms , 2023-2033

Figure 261: MEA Market Value (US$ Mn) Analysis by Population Type, 2018-2033

Figure 262: MEA Market Value Share (%) and BPS Analysis by Population Type, 2023-2033

Figure 263: MEA Market Y-o-Y Growth (%) Projections by Population Type, 2023-2033

Figure 264: MEA Market Value (US$ Mn) Analysis by Route of Administration, 2018-2033

Figure 265: MEA Market Value Share (%) and BPS Analysis by Route of Administration, 2023-2033

Figure 266: MEA Market Y-o-Y Growth (%) Projections by Route of Administration, 2023-2033

Figure 267: MEA Market Value (US$ Mn) Analysis by Treatment, 2018-2033

Figure 268: MEA Market Value Share (%) and BPS Analysis by Treatment, 2023-2033

Figure 269: MEA Market Y-o-Y Growth (%) Projections by Treatment, 2023-2033

Figure 270: MEA Market Value (US$ Mn) Analysis by End-Users, 2018-2033

Figure 271: MEA Market Value Share (%) and BPS Analysis by End-Users, 2023-2033

Figure 272: MEA Market Y-o-Y Growth (%) Projections by End-Users, 2023-2033

Figure 273: MEA Market Attractiveness by Diagnosis, 2023-2033

Figure 274: MEA Market Attractiveness by Disease Type, 2023-2033

Figure 275: MEA Market Attractiveness by Symptoms , 2023-2033

Figure 276: MEA Market Attractiveness by Population Type, 2023-2033

Figure 277: MEA Market Attractiveness by Route of Administration, 2023-2033

Figure 278: MEA Market Attractiveness by Treatment, 2023-2033

Figure 279: MEA Market Attractiveness by End-Users, 2023-2033

Figure 280: MEA Market Attractiveness by Country, 2023-2033

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports

Recommendations

Healthcare

Membranous Nephropathy Treatment Market

Published : October 2020

Healthcare

IgE Allergy Blood Tests Market

Published : January 2020

Healthcare

Diabetic Nephropathy Market

Published : December 2016

Google translate

IgA Nephropathy Market